Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer

Mediators of Inflammation

Volumn 2012, Issue , 2012, Pages

  Zhu, Zhaowei ^a   Shen, Zhoujun ^a   Xu, Chen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE; CHEMOKINE RECEPTOR; CYCLOOXYGENASE 2; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; PROSTAGLANDIN E; TRANSCRIPTION FACTOR; PTGS2 PROTEIN, HUMAN;

BLADDER CANCER; BONE MARROW CELL; CANCER CHEMOTHERAPY; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; BLADDER TUMOR; METABOLISM;

ANTINEOPLASTIC AGENTS; CHEMOKINES; CYCLOOXYGENASE 2; CYTOKINES; HUMANS; INFLAMMATION; TRANSCRIPTION FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84864914362     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2012/528690     Document Type: Review

References (108)

1. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics, 2010 CA: A Cancer Journal for Clinicians 2010 60 5 277 300
2. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Bhle A., Palou-Redorta J., Rouprt M., EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update European Urology 2011 59 6 997 1008
3. Mantovani A., Allavena P., Sica A., Balkwill F., Cancer-related inflammation Nature 2008 454 7203 436 444
4. Grivennikov S. I., Greten F. R., Karin M., Immunity, inflammation, and cancer Cell 2010 140 6 883 899
5. Allavena P., Germano G., Marchesi F., Mantovani A., Chemokines in cancer related inflammation Experimental Cell Research 2011 317 5 664 673
6. Germano G., Allavena P., Mantovani A., Cytokines as a key component of cancer-related inflammation Cytokine 2008 43 3 374 379
7. Lazennec G., Richmond A., Chemokines and chemokine receptors: new insights into cancer-related inflammation Trends in Molecular Medicine 2010 16 3 133 144
8. Mantovani A., Savino B., Locati M., Zammataro L., Allavena P., Bonecchi R., The chemokine system in cancer biology and therapy Cytokine Growth Factor Reviews 2010 21 1 27 39
9. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation Cell 2011 144 5 646 674
10. Mantovani A., Molecular pathways linking inflammation and cancer Current Molecular Medicine 2010 10 4 369 373
11. Sylvester R. J., Oosterlinck W., van der Meijden A. P., A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials The Journal of Urology 2004 171 6, part 1 2186 2190 (Pubitemid 38625431)
12. Pawinski A., Sylvester R., Kurth K. H., Bouffioux C., Van Der Meijden A., Parmar M. K. B., Bijnens L., A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer The Journal of Urology 1996 156 6 1934 1941 (Pubitemid 26378022)
13. Maeda T., Kikuchi E., Matsumoto K., Miyajima A., Oya M., Urinary pH is highly associated with tumor recurrence during intravesical mitomycin c therapy for nonmuscle invasive bladder tumor The Journal of Urology 2011 185 3 802 806
14. Sherif A., Holmberg L., Rintala E., Mestad O., Nilsson J., Nilsson S., Malmstrm P. U., Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies European Urology 2004 45 3 297 303 (Pubitemid 38221402)
15. Stenzl A., Cowan N. C., De Santis M., Kuczyk M. A., Merseburger A. S., Ribal M. J., Sherif A., Witjes J. A., Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines European Urology 2011 59 6 1009 1018
16. Martinez-Pineiro J. A., Gonzalez M. M., Arocena F., Flores N., Ramos Roncero C., Portillo J. A., Escudero A., Jimenez Cruz F., Isorna S., Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study The Journal of Urology 1995 153 3, part 2 964 973
17. von der Maase H., Sengelov L., Roberts J. T., Ricci S., Dogliotti L., Oliver T., Moore M. J., Zimmermann A., Arning M., Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer Journal of Clinical Oncology 2005 23 21 4602 4608 (Pubitemid 46224062)
18. Sternberg C. N., de Mulder P. H., Schornagel J. H., Théodore C., Fossa S. D., Van Oosterom A. T., Witjes F., Spina M., Van Groeningen C. J., De Balincourt C., Collette L., Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancer protocol no. 30924 Journal of Clinical Oncology 2001 19 10 2638 2646 (Pubitemid 32441368)
19. von der Maase H., Hansen S. W., Roberts J. T., Dogliotti L., Oliver T., Moore M. J., Bodrogi I., Albers P., Knuth A., Lippert C. M., Kerbrat P., Sanchez Rovira P., Wersall P., Cleall S. P., Roychowdhury D. F., Tomlin I., Visseren-Grul C. M., Conte P. F., Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study Journal of Clinical Oncology 2000 18 17 3068 3077
20. Stein J. P., Lieskovsky G., Cote R., Groshen S., Feng A. C., Boyd S., Skinner E., Bochner B., Thangathurai D., Mikhail M., Raghavan D., Skinner D. G., Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients Journal of Clinical Oncology 2001 19 3 666 675 (Pubitemid 32120143)
21. Dufresne M., Dumas G., Asselin., Carrier C., Pouliot M., Reyes-Moreno C., Pro-inflammatory type-1 and anti-inflammatory type-2 macrophages differentially modulate cell survival and invasion of human bladder carcinoma T24 cells Molecular Immunology 2011 48 12-13 1556 1567
22. Yang H., Kim C., Kim M. J., Schwendener R. A., Alitalo K., Heston W., Kim I., Kim W. J., Koh G. Y., Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer Molecular Cancer 2011 10, article 36
23. Klein R. D., Van Pelt C. S., Sabichi A. L., Dela Cerda J., Fischer S. M., Frstenberger G., Mller-Decker K., Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression Cancer Research 2005 65 5 1808 1813 (Pubitemid 40478608)
24. Chen W. T., Hung W. C., Kang W. Y., Huang Y. C., Su Y. C., Yang C. H., Chai C. Y., Overexpression of cyclooxygenase-2 in urothelial carcinoma in conjunction with tumor-associated-macrophage infiltration, hypoxia-inducible factor-1 expression, and tumor angiogenesis APMIS: Acta Pathologica, Microbiologica et Immunologica Scandinavica 2009 117 3 176 184
25. Chai C. Y., Chen W. T., Hung W. C., Kang W. Y., Huang Y. C., Su Y. C., Yang C. H., Hypoxia-inducible factor-1 expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma Journal of Clinical Pathology 2008 61 5 658 664
26. Hanada T., Nakagawa M., Emoto A., Nomura T., Nasu N., Nomura Y., Prognostic value of tumor-associated macrophage count in human bladder cancer International Journal of Urology 2000 7 7 263 269 (Pubitemid 30440592)
27. Ayari C., LaRue H., Hovington H., Decobert M., Harel F., Bergeron A., Ttu B., Lacombe L., Fradet Y., Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy European Urology 2009 55 6 1386 1395
28. Takayama H., Nishimura K., Tsujimura A., Nakai Y., Nakayama M., Aozasa K., Okuyama A., Nonomura N., Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation The Journal of Urology 2009 181 4 1894 1900
29. Onita T., Guang Ji P., Xuan J. W., Sakai H., Kanetake H., Maxwell P. H., Fong G. H., Gabril M. Y., Moussa M., Chin J. L., Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2 correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer Clinical Cancer Research 2002 8 2 471 480 (Pubitemid 34193967)
30. Koga F., Kageyama Y., Kawakami S., Fujii Y., Hyochi N., Ando N., Takizawa T., Saito K., Iwai A., Masuda H., Kihara K., Prognostic significance of endothelial Per-Arnt-Sim domain protein 1/hypoxia-inducible factor-2 expression in a subset of tumor associated macrophages in invasive bladder cancer The Journal of Urology 2004 171 3 1080 1084 (Pubitemid 38327531)
31. Porta C., Larghi P., Rimoldi M., Grazia Totaro M., Allavena P., Mantovani A., Sica A., Cellular and molecular pathways linking inflammation and cancer Immunobiology 2009 214 9-10 761 777
32. Marx J., Cancer immunology: cancer's bulwark against immune attack: MDS cells Science 2008 319 5860 154 156
33. Eruslanov E., Daurkin I., Vieweg J., Daaka Y., Kusmartsev S., Aberrant PGE 2 metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells International Immunopharmacology 2011 11 7 848 855
34. Eruslanov E., Neuberger M., Daurkin I., Perrin G. Q., Algood C., Dahm P., Rosser C., Vieweg J., Gilbert S. M., Kusmartsev S., Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer International Journal of Cancer 2012 130 5 1109 1119
35. Fridlender Z. G., Sun J., Singhal S., Kapoor V., Cheng G., Suzuki E., Albelda S. M., Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms Molecular Therapy 2010 18 11 1947 1959
36. Zhang X., Shi X., Li J., A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer The Journal of Urology 2012 187 3 1071 1079
37. Naoe M., Ogawa Y., Takeshita K., Morita J., Iwamoto S., Miyazaki A., Yoshida H., Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and T cells International Journal of Urology 2007 14 6 532 538 (Pubitemid 46985528)
38. Furukawa J., Hara I., Nagai H., Yao A., Oniki S., Fujisawa M., Interleukin-21 gene transfection into mouse bladder cancer cells results in tumor rejection through the cytotoxic T lymphocyte response The Journal of Urology 2006 176 3 1198 1203 (Pubitemid 44142565)
39. Agarwal A., Agrawal U., Verma S., Mohanty N. K., Saxena S., Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre-and post-intravesical combination immunotherapy Immunopharmacology and Immunotoxicology 2010 32 2 348 356
40. Satyam A., Singh P., Badjatia N., Seth A., Sharma A., A disproportion of TH1/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder Urologic Oncology 2011 29 1 58 65
41. Codolo G., Fassan M., Munari F., Volpe A., Bassi P., Rugge M., Pagano F., D'Elios M. M., de Bernard M., HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response Cancer Immunology, Immunotherapy 2012 61 1 31 40
42. Chi L. J., Lu H. T., Li G. L., Wang X. M., Su Y., Xu W. H., Shen B. Z., Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma Clinical and Experimental Immunology 2010 161 3 480 489
43. Lo S. Z., Steer J. H., Joyce D. A., TNF- renders macrophages resistant to a range of cancer chemotherapeutic agents through NF- B-mediated antagonism of apoptosis signalling Cancer Letters 2011 307 1 80 92
44. Feng C. C., Wang P. H., Ding Q., Guan M., Zhang Y. F., Jiang H. W., Wen H., Wu Z., Expression of pigment epithelium-derived factor and tumor necrosis factor- is correlated in bladder tumor and is related to tumor angiogenesis. Urologic Oncology. In press
45. Lee S. J., Park S. S., Cho Y. H., Park K., Kim E. J., Jung K. H., Kim S. K., Kim W. J., Moon S. K., Activation of matrix metalloproteinase-9 by TNF- in human urinary bladder cancer HT1376 cells: The role of MAP kinase signaling pathways Oncology Reports 2008 19 4 1007 1013 (Pubitemid 351802673)
46. Lee E. J., Kim W. J., Moon S. K., Cordycepin suppresses TNF-alpha-induced invasion, migration and matrix metalloproteinase-9 expression in human bladder cancer cells Phytotherapy Research 2010 24 12 1755 1761
47. Seddighzadeh M., Steineck G., Jansson O., Larsson P., Wijkstrm H., Adolfsson J., Portwood N., Hansson J., Linder S., Low interleukin-1 messenger RNA levels predict decreased overall survival time of patients with urinary bladder carcinoma British Journal of Cancer 2001 84 3 329 334 (Pubitemid 32154424)
48. Seddighzadeh M., Larsson P., Ulfgren A. C., Onelv E., Berggren P., Tribukait B., Torstensson A., Norming U., Wijkstrm H., Linder S., Steineck G., Low IL-1 expression in bladder cancer tissue and survival European Urology 2003 43 4 362 368 (Pubitemid 36427454)
49. Hong D. S., Angelo L. S., Kurzrock R., Interleukin-6 and its receptor in cancer: implications for translational therapeutics Cancer 2007 110 9 1911 1928 (Pubitemid 350036849)
50. Leibovici D., Grossman H. B., Dinney C. P., Millikan R. E., Lerner S., Wang Y., Gu J., Dong Q., Wu X., Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival Journal of Clinical Oncology 2005 23 24 5746 5756
51. Okamoto M., Hattori K., Oyasu R., Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro International Journal of Cancer 1997 72 1 149 154 (Pubitemid 27314652)
52. Ito M., Saito K., Yasuda Y., Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel Urology 2011 78 5 1131 1135
53. Park Y. H., Baik K. D., Lee Y. J., Ku J. H., Kim H. H., Kwak C., Late recurrence of renal cell carcinoma 5 years after surgery: clinicopathological characteristics and prognosis. British Journal of Urology International. In press
54. Gakis G., Todenhoefer T., Renninger M., Schilling D., Sievert K. D., Schwentner C., Stenzl A., Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score British Journal of Urology International 2011 108 11 1800 1805
55. Pignot G., Bieche I., Vacher S., Get C., Vieillefond A., Debré B., Lidereau R., Amsellem-Ouazana D., Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker European Urology 2009 56 4 678 688
56. Sheryka E., Wheeler M. A., Hausladen D. A., Weiss R. M., Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma Urology 2003 62 1 162 166 (Pubitemid 36802107)
57. Inoue K., Slaton J. W., Kim S. J., Perrotte P., Eve B. Y., Bar-Eli M., Radinsky R., Dinney C. P. N., Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer Cancer Research 2000 60 8 2290 2299 (Pubitemid 30225196)
58. Nishizawa K., Nishiyama H., Oishi S., Tanahara N., Kotani H., Mikami Y., Toda Y., Evans B. J., Peiper S. C., Saito R., Watanabe J., Fujii N., Ogawa O., Fluorescent imaging of high-grade bladder cancer using a specific antagonist for chemokine receptor CXCR4 International Journal of Cancer 2010 127 5 1180 1187
59. Niedermeier M., Hennessy B. T., Knight Z. A., Henneberg M., Hu J., Kurtova A. V., Wierda W. G., Keating M. J., Shokat K. M., Burger J. A., Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach Blood 2009 113 22 5549 5557
60. Ruffini P. A., Morandi P., Cabioglu N., Altundag K., Cristofanilli M., Manipulating the chemokine-chemokine receptor network to treat cancer Cancer 2007 109 12 2392 2404 (Pubitemid 46906457)
61. Schottenfeld D., Beebe-Dimmer J., Chronic inflammation: a common and important factor in the pathogenesis of neoplasia CA: A Cancer Journal for Clinicians 2006 56 2 69 83
62. Chan A. T., Ogino S., Fuchs C. S., Aspirin and the risk of colorectal cancer in relation to the expression of COX-2 The New England Journal of Medicine 2007 356 21 2131 2142 (Pubitemid 47010839)
63. Flossmann E., Rothwell P. M., Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies The Lancet 2007 369 9573 1603 1613 (Pubitemid 46710123)
64. Koehne C. H., Dubois R. N., COX-2 inhibition and colorectal cancer Seminars in Oncology 2004 31 2, supplement 7 12 21 (Pubitemid 38879410)
65. Dhawan D., Craig B. A., Cheng L., Snyder P. W., Mohammed S. I., Stewart J. C., Zheng R., Loman R. A., Foster R. S., Knapp D. W., Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder Molecular Cancer Therapeutics 2010 9 5 1371 1377
66. Back M., Yin L., Ingelsson E., Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. European Heart Journal. In press
67. Margulis V., Shariat S. F., Ashfaq R., Thompson M., Sagalowsky A. I., Hsieh J. T., Lotan Y., Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder The Journal of Urology 2007 177 3 1163 1168 (Pubitemid 46216369)
68. Sabichi A. L., Lee J. J., Grossman H. B., A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer Cancer Prevention Research 2011 4 10 1580 1589
69. Mohammed S. I., Bennett P. F., Craig B. A., Glickman N. W., Mutsaers A. J., Snyder P. W., Widmer W. R., DeGortari A. E., Bonney P. L., Knapp D. W., Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer Cancer Research 2002 62 2 356 358 (Pubitemid 34106402)
70. Mohammed S. I., Craig B. A., Mutsaers A. J., Glickman N. W., Snyder P. W., deGortari A. E., Schlittler D. L., Coffman K. T., Bonney P. L., Knapp D. W., Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer Molecular Cancer Therapeutics 2003 2 2 183 188
71. Shi Y., Cui L., Dai G., Chen J., Pan H., Song L., Cheng S., Wang X., Elevated prostaglandin E2 level via cPLA2-COX-2-mPGES-1 pathway involved in bladder carcinogenesis induced by terephthalic acid-calculi in Wistar rats Prostaglandins Leukotrienes and Essential Fatty Acids 2006 74 5 309 315
72. Gee J., Lee I. L., Grossman H. B., Sabichi A. L., Forced COX-2 expression induces PGE2 and invasion in immortalized urothelial cells Urologic Oncology 2008 26 6 641 645
73. Eschwge P., Ferlicot S., Droupy S., Ba N., Conti M., Loric S., Coindard G., Denis I., Ferretti L., Cornelius A., Legrand A., Bedossa P., Benot G., Jardin A., Scardino P., A histopathologic investigation of PGE2 pathways as predictors of proliferation and invasion in urothelial carcinomas of the bladder European Urology 2003 44 4 435 441 (Pubitemid 37185668)
74. Wheeler M. A., Hausladen D. A., Yoon J. H., Weiss R. M., Prostaglandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer The Journal of Urology 2002 168 4, part 1 1568 1573 (Pubitemid 35034191)
75. Ehsan A., Sommer F., Schmidt A., Klotz T., Koslowski J., Niggemann S., Jacobs G., Engelmann U., Addicks K., Bloch W., Nitric oxide pathways in human bladder carcinoma: the distribution of nitric oxide synthases, soluble guanylyl cyclase, cyclic guanosine monophosphate, and nitrotyrosine Cancer 2002 95 11 2293 2301 (Pubitemid 35351134)
76. Hosseini A., Koskela L. R., Ehrén I., Aguilar-Santelises M., Sirsj A., Wiklund N. P., Enhanced formation of nitric oxide in bladder carcinoma in situ and in BCG treated bladder cancer Nitric Oxide 2006 15 4 337 343 (Pubitemid 44647888)
77. Morcos E., Jansson O. T., Adolfsson J., Ehrén I., Wiklund N. P., Bacillus calmette-guerin induces long-term local formation of nitric oxide in the bladder via the induction of nitric oxide synthase activity in urothelial cells The Journal of Urology 2001 165 2 678 682 (Pubitemid 32060499)
78. Lavagna C., Del Soldato P., Burgaud J. L., Rampal P., Nitric oxide-releasing non steroidal anti-inflammatory drugs: a new generation of anti-tumoral molecules Current Cancer Drug Targets 2003 3 6 407 426 (Pubitemid 38017478)
79. Huguenin S., Vacherot F., Kheuang L., Fleury-Feith J., Jaurand M. C., Bolla M., Riffaud J. P., Chopin D. K., Antiproliferative effect of nitrosulindac (NCX 1102), a new nitric oxide-donating non-steroidal anti-inflammatory drug, on human bladder carcinoma cell lines Molecular Cancer Therapeutics 2004 3 3 291 298 (Pubitemid 39193704)
80. Fabbri F., Brigliadori G., Ulivi P., Tesei A., Vannini I., Rosetti M., Bravaccini S., Amadori D., Bolla M., Zoli W., Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells Apoptosis 2005 10 5 1095 1103 (Pubitemid 41285585)
81. Kim J. K., Kim K. D., Lee E., Lim J. S., Cho H. J., Yoon H. K., Cho M. Y., Baek K. E., Park Y. P., Paik S. G., Choe Y. K., Lee H. G., Up-regulation of Bfl-1/A1 via NF- B activation in cisplatin-resistant human bladder cancer cell line Cancer Letters 2004 212 1 61 70 (Pubitemid 38887721)
82. Levidou G., Saetta A. A., Korkolopoulou P., Papanastasiou P., Gioti K., Pavlopoulos P., Diamantopoulou K., Thomas-Tsagli E., Xiromeritis K., Patsouris E., Clinical significance of nuclear factor (NF)- B levels in urothelial carcinoma of the urinary bladder Virchows Archiv 2008 452 3 295 304
83. Li Y., Xing D., Chen Q., Chen W. R., Enhancement of chemotherapeutic agent-induced apoptosis by inhibition of NF- B using ursolic acid International Journal of Cancer 2010 127 2 462 473
84. Kamat A. M., Sethi G., Aggarwal B. B., Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor- B and nuclear factor- B-regulated gene products in IFN- -sensitive and IFN- -resistant human bladder cancer cells Molecular Cancer Therapeutics 2007 6 3 1022 1030 (Pubitemid 46554572)
85. Bromberg J., Wang T. C., Inflammation and cancer: IL-6 and STAT3 complete the link Cancer Cell 2009 15 2 79 80
86. Wang L., Yi T., Kortylewski M., Pardoll D. M., Zeng D., Yu H., IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway The Journal of Experimental Medicine 2009 206 7 1457 1464
87. Lee H., Herrmann A., Deng J. H., Kujawski M., Niu G., Li Z., Forman S., Jove R., Pardoll D. M., Yu H., Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors Cancer Cell 2009 15 4 283 293
88. Chen C. L., Cen L., Kohout J., Hutzen B., Chan C., Hsieh F. C., Loy A., Huang V., Cheng G., Lin J., Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival Molecular Cancer 2008 7, article 78
89. Chen R. J., Ho Y. S., Guo H. R., Wang Y. J., Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells Toxicological Sciences 2010 115 1 118 130
90. Itoh M., Murata T., Suzuki T., Shindoh M., Nakajima K., Imai K., Yoshida K., Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells Oncogene 2006 25 8 1195 1204
91. Kim W. Y., Kaelin W. G., Role of VHL gene mutation in human cancer Journal of Clinical Oncology 2004 22 24 4991 5004 (Pubitemid 46646218)
92. Kaufman B., Scharf O., Arbeit J., Ashcroft M., Brown J. M., Bruick R. K., Chapman J. D., Evans S. M., Giaccia A. J., Harris A. L., Huang E., Johnson R., Kaelin W., Koch C. J., Maxwell P., Mitchell J., Neckers L., Powis G., Rajendran J., Semenza G. L., Simons J., Storkebaum E., Welch M. J., Whitelaw M., Melillo G., Ivy S. P., Proceedings of the oxygen homeostasis/hypoxia meeting Cancer Research 2004 64 9 3350 3356 (Pubitemid 38581443)
93. Rius J., Guma M., Schachtrup C., Akassoglou K., Zinkernagel A. S., Nizet V., Johnson R. S., Haddad G. G., Karin M., NF- B links innate immunity to the hypoxic response through transcriptional regulation of HIF-1 Nature 2008 453 7196 807 811 (Pubitemid 351793778)
94. Brdos J. I., Ashcroft M., Hypoxia-inducible factor-1 and oncogenic signalling BioEssays 2004 26 3 262 269 (Pubitemid 38325667)
95. Jones A., Fujiyama C., Blanche C., Moore J. W., Fuggle S., Cranston D., Bicknell R., Harris A. L., Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 and hypoxia-inducible factor-2 in human bladder tumors and cell lines Clinical Cancer Research 2001 7 5 1263 1272 (Pubitemid 32708679)
96. Theodoropoulos V. E., Lazaris A. C., Sofras F., Gerzelis I., Tsoukala V., Ghikonti I., Manikas K., Kastriotis I., Hypoxia-inducible factor 1 expression correlates with angiogenesis and unfavorable prognosis in bladder cancer European Urology 2004 46 2 200 208 (Pubitemid 38902737)
97. Tickoo S. K., Milowsky M. I., Dhar N., Dudas M. E., Gallagher D. J., Al-Ahmadie H., Gopalan A., Fine S. W., Ishill N., Bajorin D. F., Reuter V. E., Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications British Journal of Urology International 2011 107 5 844 849
98. Fechner G., Dederichs F., Schmidt D., Mller S., Vaupel P., Albers P., Hyperoxia-induced improvement of the in vitro response to gemcitabine in transitional cell carcinoma Anticancer Research 2005 25 5 3413 3418 (Pubitemid 41109984)
99. Linden J., Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection Annual Review of Pharmacology and Toxicology 2001 41 775 787 (Pubitemid 32385906)
100. Sitkovsky M., Lukashev D., Regulation of immune cells by local-tissue oxygen tension: HIF1 and adenosine receptors Nature Reviews Immunology 2005 5 9 712 721 (Pubitemid 43086172)
101. Phelps P. T., Anthes J. C., Correll C. C., Characterization of adenosine receptors in the human bladder carcinoma T24 cell line European Journal of Pharmacology 2006 536 1-2 28 37
102. Cekic C., Sag D., Li Y., Theodorescu D., Strieter R. M., Linden J., Adenosine A2B receptor blockade slows growth of bladder and breast tumors Journal of Immunology 2012 188 1 198 205
103. Martins I., Tesniere A., Kepp O., Michaud M., Schlemmer F., Senovilla L., Séror C., Métivier D., Perfettini J. L., Zitvogel L., Kroemer G., Chemotherapy induces ATP release from tumor cells Cell Cycle 2009 8 22 3723 3728
104. Deaglio S., Dwyer K. M., Gao W., Friedman D., Usheva A., Erat A., Chen J. F., Enjyoji K., Linden J., Oukka M., Kuchroo V. K., Strom T. B., Robson S. C., Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression The Journal of Experimental Medicine 2007 204 6 1257 1265 (Pubitemid 46919862)
105. Stella J., Bavaresco L., Braganhol E., Rockenbach L., Farias P. F., Wink M. R., Azambuja A. A., Barrios C. H., Morrone F. B., Oliveira Battastini A. M., Differential ectonucleotidase expression in human bladder cancer cell lines Urologic Oncology 2010 28 3 260 267
106. Clayton A., Al-Taei S., Webber J., Mason M. D., Tabi Z., Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production Journal of Immunology 2011 187 2 676 683
107. Vakkila J., Lotze M. T., Inflammation and necrosis promote tumour growth Nature Reviews Immunology 2004 4 8 641 648 (Pubitemid 39025049)
108. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G., Immunological aspects of cancer chemotherapy Nature Reviews Immunology 2008 8 1 59 73